Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Advertisement
Mary GreccoNon-Small Cell Lung Cancer | February 28, 2024
A study analyzed the cost-effectiveness of two different treatment methods in NSCLC.
Read More
Eileen Koutnik-FotopoulosNon-Small Cell Lung Cancer | February 28, 2024
Researchers evaluated the safety, tolerability, and antitumor activity of Dato-DXd in treating NSCLC.
Mary GreccoNon-Small Cell Lung Cancer | February 23, 2024
A study evaluated the prognosis of patients with locally advanced and metastatic NSCLC who underwent prior TKI.
Mary GreccoNon-Small Cell Lung Cancer | February 23, 2024
The TROPION-Lung07 trial will evaluate Dato-DXd plus pembrolizumab in patients with advanced/metastatic NSCLC.
Kaitlyn KoskoNon-Small Cell Lung Cancer | February 21, 2024
Patients with NSCLC who have NTRK mutations have a survival advantage with immune checkpoint inhibitors.
Kaitlyn KoskoNon-Small Cell Lung Cancer | February 21, 2024
The first in-human study of datopotamab deruxtecan showed the optimal dose for treating NSCLC.
Kaitlyn KoskoNon-Small Cell Lung Cancer | February 21, 2024
Preoperative tissue diagnosis of NSCLC is associated with increased lymph node harvest, and upstaging rates.
Eileen Koutnik-FotopoulosNon-Small Cell Lung Cancer | February 20, 2024
The effect of genomic alterations in NSCLC on brain metastases remains unclear.
Kaitlyn KoskoNon-Small Cell Lung Cancer | February 20, 2024
Age at the time of surgery and race play a role in which patients may begin smoking again following surgery for NSCLC.
Kaitlyn KoskoNon-Small Cell Lung Cancer | February 20, 2024
The (pro)renin receptor—or (P)RR—protein may play a significant role in lung cancer.
Rob DillardNon-Small Cell Lung Cancer | February 14, 2024
A combination of targeted therapy and immunotherapy may benefit patients with non-small cell lung cancer.
Rob DillardNon-Small Cell Lung Cancer | February 12, 2024
Accurately diagnosing pneumonitis in patients with inoperable stage III non-small cell lung cancer is challenging.
Mary GreccoESMO 2023: Focus on Lung Cancer | January 31, 2024
A study analyzed the clinicopathological characteristics of small-scale ROS1 mutations in patients with NSCLC.
Mary GreccoESMO 2023: Focus on Lung Cancer | January 31, 2024
A study looked at the modulating effects of neoadjuvant immunotherapy and CRT on TDLN in patients with T2-4NO-1 NSCLC.
Mary GreccoESMO 2023: Focus on Lung Cancer | January 31, 2024
A study compared IMPT with IMRT its impact on hematological toxicity and effect on durvalumab treatment on NSCLC.
Mary GreccoESMO 2023: Focus on Lung Cancer | January 31, 2024
Results of a study examining the association between HRD status and postsurgical therapeutic options in early-stage NSCLC.
Mary GreccoESMO 2023: Focus on Lung Cancer | January 31, 2024
A study investigated the use of a structured multidisciplinary review for the diagnosis of IO pneumonitis in NSCLC.
Eileen Koutnik-FotopoulosNon-Small Cell Lung Cancer | January 26, 2024
Researchers examined the demographic and clinical outcomes in patients with KRAS-mutated tumors, using patients with NSCLC.
Eileen Koutnik-FotopoulosNon-Small Cell Lung Cancer | January 26, 2024
The optimal duration of ICI ± chemotherapy for patients with advanced non-small cell lung cancer remains unclear.
Kaitlyn KoskoNon-Small Cell Lung Cancer | January 25, 2024
Perioperative anesthetic factors may affect the prognosis of patients with NSCLC following surgery.
Advertisement
Advertisement
Advertisement
Latest News

February 28, 2024